Mary Susan Brady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mary Susan Brady has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Daniel G. Coit
29 shared publicationsKatherine S. Panageas
23 shared publicationsKlaus J. Busam
23 shared publicationsCharlotte E. Ariyan
22 shared publications- Alexander Noor Shoushtari
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
21 shared publications - Allison Betof Warner
Stanford University School of Medicine, Stanford, California, USA
21 shared publications
Latest Publications
- 5 February 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (2) , e2354762
Smoking and Melanoma Outcomes—Another Reason to Quit
Do you need another reason to encourage your patients to stop smoking? Smoking increases the risk of a myriad of diseases and is associated with cancer incidenc
- 5 February 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (2) , e2354762
Smoking and Melanoma Outcomes—Another Reason to Quit
Do you need another reason to encourage your patients to stop smoking? Smoking increases the risk of a myriad of diseases and is associated with cancer incidenc
- 30 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 91-96
Adjuvant therapy for stage IIB + IIC melanoma
- 30 November 2023
- Published by Wiley in Journal of Surgical Oncology
- Vol. 129 (1) , 91-96
Adjuvant therapy for stage IIB + IIC melanoma
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Demographic data for the PD-1 treated subset.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Demographic data for the PD-1 treated subset.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Demographic data for the PD-1 treated subset.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Demographic data for the PD-1 treated subset.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Clinical data for each sequenced sample.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Clinical data for each sequenced sample.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Kaplan-Meier curves for overall survival. (A) PD-1 monotherapy by driver class. (B) nivolumab plus ipilimumab by driver class. (C) PD-1 monotherapy by primary site of melanoma. (D) nivolumab plus ipilimumab by primary site of melanoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Kaplan-Meier curves for overall survival. (A) PD-1 monotherapy by driver class. (B) nivolumab plus ipilimumab by driver class. (C) PD-1 monotherapy by primary site of melanoma. (D) nivolumab plus ipilimumab by primary site of melanoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
CONSORT diagram of samples that underwent MSK-IMPACT sequencing and analyzed for clinical outcomes with frontline PD-1 based therapy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
(A) Oncoprint showing similar rates of driver alterations between cutaneous melanomas and melanomas of unknown primary. This suggests the vast majority of melanomas of unknown primary arose from regressed cutaneous sites. (B) Sequenced melanomas arising in females (N=244) have a lower median TMB than those arising in males (N=475; 15.7 vs 17.6 mut/Mb, p= 0.024). (C) The median fraction of alterations associated with an ultraviolet signature varies by MAPK Driver (p=9.6e-9). (D) The median fraction of alterations associated with an ultraviolet signature varies by primary site (p=3.9e-10).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
(A) Oncoprint showing similar rates of driver alterations between cutaneous melanomas and melanomas of unknown primary. This suggests the vast majority of melanomas of unknown primary arose from regressed cutaneous sites. (B) Sequenced melanomas arising in females (N=244) have a lower median TMB than those arising in males (N=475; 15.7 vs 17.6 mut/Mb, p= 0.024). (C) The median fraction of alterations associated with an ultraviolet signature varies by MAPK Driver (p=9.6e-9). (D) The median fraction of alterations associated with an ultraviolet signature varies by primary site (p=3.9e-10).